<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03664388</url>
  </required_header>
  <id_info>
    <org_study_id>Hospital Alvaro Cunqueiro</org_study_id>
    <nct_id>NCT03664388</nct_id>
  </id_info>
  <brief_title>Registry of Acute Coronary Syndrome From University Hospital of Vigo</brief_title>
  <acronym>CardioCHUVI</acronym>
  <official_title>Registry of Patients Admitted by Acute Coronary Syndrome to University Hospital of Vigo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Álvaro Cunqueiro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Álvaro Cunqueiro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CardoCHUVI registry was aim to study ischemic and bleeding complication after an acute
      coronary syndrome (ACS), both in-hospital and follow-up events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CardioCHUVI is a retrospective study aim to analyze all consecutively patients admitted by
      acute coronary syndrome to University Hospital Alvaro Cunqueiro of Vigo, between January 2010
      to January 2018

      The objective of the project was to study cardiac and bleeding complications, such as
      reinfarction, heart failure, atrial fibrillation, stroke, and bleeding events, together with
      all-cause and cardiac mortality
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2016</start_date>
  <completion_date type="Anticipated">February 1, 2020</completion_date>
  <primary_completion_date type="Actual">September 6, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>Through study completion, an average of 3 years</time_frame>
    <description>Death for any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reinfarction</measure>
    <time_frame>Through study completion, an average of 3 years</time_frame>
    <description>New spontaneous acute myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>Through study completion, an average of 3 years</time_frame>
    <description>Any bleeding according to BARC definition (from 1 to 5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke</measure>
    <time_frame>Through study completion, an average of 3 years</time_frame>
    <description>Ischemic stroke documented in CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer</measure>
    <time_frame>Through study completion, an average of 3 years</time_frame>
    <description>Any type of malignant cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Failure</measure>
    <time_frame>Through study completion, an average of 3 years</time_frame>
    <description>Heart Failure admissions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atrial Fibrillation</measure>
    <time_frame>Through study completion, an average of 3 years</time_frame>
    <description>Atrial fibrillation documented in ECG</description>
  </secondary_outcome>
  <enrollment type="Anticipated">8000</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dual antiplatelet therapy with ticagrelor/prasuglre</intervention_name>
    <description>Compare bleeding and ischemic events according to the type and duration of dual antiplatelet therapy</description>
    <other_name>Dual antiplatelet therapy with clopidogrel</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients admitted by acute coronary syndrome in the University Hospital Alvaro
        Cunqueiro of Vigo between January 2010 to January 2018
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient admitted to University Hospital Alvaro Cunqueiro of Vigo for acute
             coronary syndrome.

        Exclusion Criteria:

          -  Secondary acute coronary syndromes during a hospital admission for another cause (i.e.
             acute myocardial infarction in the context of a sepsis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emad Abu-Assi, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Álvaro Cunqueiro, Vigo, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sergio Raposeiras-Roubín, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Álvaro Cunqueiro, Vigo, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andres Iñiguez-Romo, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital Álvaro Cunqueiro, Vigo, Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sergio Raposeiras Roubín, MD, PhD</last_name>
    <phone>0034 620170387</phone>
    <email>raposeiras26@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emad Abu Assi, MD, PhD</last_name>
    <email>eabuassi@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Cardiology, Hospital Álvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36312</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ANDRES IÑIGUEZ ROMO, MD, PhD</last_name>
      <email>andres.iniguez.romo@sergas.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 6, 2018</study_first_submitted>
  <study_first_submitted_qc>September 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2018</study_first_posted>
  <last_update_submitted>September 7, 2018</last_update_submitted>
  <last_update_submitted_qc>September 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Coronary Syndrome; Bleeding; Dual antiplatelet therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Registry of all consecutive patients admitted by acute coronary syndrome (ACS) to an university hospital in order to analyze bleeding and ischemic complications according to the type and duration of dual antiplatelet therapy</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

